Polypoidal Choroidal Vasculopathy
Conditions
Brief summary
Polypoidal choroidal vasculopathy (PCV) is a disease of the choroidal vasculature, that is often regarded as a sub-type of age-related macular degeneration (AMD). However, PCV response to anti-vascular agents differs from the response of typical AMD. This study aims at describing the evolution of the best corrected visual acuity (BCVA) in PCV patients, 28 weeks after they receive one injection of intravitreal aflibercept (2mg).
Interventions
Patient receive one intravitreal injection of 2mg aflibercept (as currently recommended in the treatment of AMD)
Sponsors
Fondation Ophtalmologique Adolphe de Rothschild
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
45 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Active polypoidal choroidal vasculopathy, * Visual acuity superior to 1/10 (20/200) and inferior to 6,25/10 (20/32) * Age above 45 * No prior intravitreal treatment, or no response to prior treatment by 3 injections of ranibizumab, or disease recurrence after more than 3 months of stability * Intravitreal injection of aflibercept is indicated by current clinical recommendations
Exclusion criteria
* Simultaneous treatment with another anti-VEGM agent * Diabetic retinopathy * Personal history of vitrectomy or uveitis * Personal history laser photocoagulation and/or verteporphin phototherapy * Tear in the pigmentary epithelium * Chorioretinitis scar * Macular atrophy in the pigmentary epithelium * Treatment with corticosteroids * Eye surgery less than 3 months before inclusion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evolution of the best corrected visual acuity (BCVA) measured on the EDTRS scale, between pre-injection and 28 weeks after injection | 28 weeks |
Countries
France
Outcome results
None listed